About the Course

Twelve checkpoint inhibitor therapies have been approved since 2011 in a wide variety of cancers, including tumor-agnostic indications for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer. Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs. Six CAR T-cell therapies have been approved since 2017 for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

Medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/ fellows are invited to attend.

Learning Objectives

As a result of attending the course, the participant will be able to:

• Describe the mechanism of action associated with checkpoint inhibitor therapies and the biologics used in the treatment of immune-related adverse events.
• Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies and CAR T-cell therapies.
• Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
• Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.